General Assembly Members
FECC, IPEC-Americas, IPEC-China, IPEC Europe, PQG, SSPEA who have full and equal voting rights at formal meetings of members. Click company names to visit their websites. Other individuals and organisations who have experience of and interest in pharmaceutical excipients may be considered for Associate membership. Associate members have no voting rights at formal meetings of members.
|President||Dr Iain Moore, Croda representing IPEC Europe|
|Vice-President||Mr Dale Carter, Evonik, representing IPEC-Americas|
|Treasurer||Mr Sylvain Bougoin, Fecc, representing Fecc|
|Quality Manager||Mr Alain Becart, Consultant|
|Senior Adviser||Mr Tony Scott, Consultant|
|Administrative Coordinator||Ms Joanne Blondiau, EXCiPACT Secretariat|
Meet The Board
Iain Moore, President
Iain is Global Head of Quality Assurance Croda Europe Ltd, a manufacturer of speciality and performance chemicals based in the United Kingdom. He has worked for Croda for 31 years, and for more 25 in various quality roles, including overseeing two UK regulatory inspections. He has contributed to the publication of European and US National Standards as well as many IPEC Guides. He was project leader for the development and delivery of the EXCiPACT Certification Scheme, and stood as its first President, and has latterly returned to the Board as the new President and Chairman of the Board succeeding Kevin McGlue who held the role since 2016 . He is also chair of the EFFCI (European Federation for Cosmetic Ingredients) GMP Committee which oversees the EFfCI GMP Guide and standard for Cosmetic Ingredients.
Dale Carter, Vice-President
Dale graduated with a BS in Chemistry from Davidson College in 1983 and an MS in Chemistry from North Carolina State University in 1988. From 2000 he spent 8 years as Manager, Product Quality & Management Systems at the Archer Daniels Midland Company in global food processing and commodities trading. From 2008 – August 2017, Dale was Global Director of Quality at the JM Huber Engineer Materials Silica Business Unit. Following the Huber acquisition by Evonik Industries on 1st September, 2017 he became Head of Quality BL Silica NAFTA responsible for the North America region where Evonik has a combination of 6 Silica plants.
Dale represented JM Huber as a member of the IPEC-Americas. He was a member of the GMP Committee from 2001 – 2010 and as Chairman from 2011-2013, During this time, he was a member of the EXCiPACT project team and he became a Board Director of EXCiPACT asbl in February 2017 representing IPEC-Americas.
Meet The Operations Team
Alain Becart, Quality Manager
Alain has a Doctorate in Industrial Pharmacy and a Masters degree in Analytical Chemistry and Quality Control. He started his career as Head of Quality Control in Pharmaceutical Manufacturing with the French offices of Ethypharm and Boehringer Ingelheim. In 1995, he joined Rhone Poulenc Rorer (a Sanofi legacy company) in their R&D – Analytical Sciences department with responsibility for clinical batches analysis and stability testing.
In 2005, he became responsible for Suppliers Quality Management worldwide within the Industrial Quality & Compliance corporate department Sanofi-Aventis, where he built a global system to manage the quality of third parties, including audits of manufacturers and distributors of pharmaceutical starting materials. He retired in October 2017 as Director Quality of Third Parties in SANOFI Global Quality based in Paris.
Since 2010, Alain has been President of the Pharmaceutical Starting Material Forum within the Quality Group of the LEEM - the professional organisation of pharmaceutical companies operating in France. In January, 2017, he became the Quality Manager of EXCiPACT asbl with responsibility for the approval of their Registered Certification Bodies and Registered Auditors, and for ensuring compliance of EXCiPACT certification actions with regards to ISO 19011 and ISO 17021 standards.
Tony Scott, Senior Adviser
Tony graduated in organic chemistry in 1965 and joined Plant Protection Ltd (PPL) as a research chemist. PPL is a legacy company of ICI Agrochemicals/Zeneca Agrochemicals/Syngenta. In 1969, he joined the R&D Directorate of Chemical Abstracts Services in Ohio re-joining ICI Agrochemicals in R&D as Senior Information Officer in 1971. He moved from R&D in 1974 into a series of increasingly responsible commercial roles in the UK and overseas, before joining the British Government in 1994 as Export Promoter for N. America.
In 1995, Tony became a Director of the UK Chemical Industries Association until 2004, when he started his own consultancy business in life sciences. His first assignment was to create and develop the Brussels-based European Fine Chemicals Group (EFCG) within CEFIC. In 2008, EFCG and IPEC Europe signed an agreement to co-develop an excipients certification project that culminated with the creation of EXCiPACT asbl in 2014. Tony had joined the project team in 2008, increasing his involvement when his EFCG assignment culminated in 2015. He is presently a Senior Adviser in the Operations Team.
Under the Articles of the Association, full Membership of EXCiPACT asbl can only be granted to trade associations or similar organisations that represent groups of organisations who have an interest in manufacturing, distributing or using pharmaceutical excipients, and Competent Authorities responsible for upholding safety and quality standards for excipients. All those interested in becoming a member should contact the EXCiPACT Secretariat at firstname.lastname@example.org or complete our contact form in the first instance.
EXCiPACT asbl is a Belgian not-for-profit association following the rules set by the Articles of Association. To support the values and related perceptions of our industry, it is essential that EXCiPACT asbl not only complies with statutory provisions and legal requirements regarding the essential features of the association (e.g. conduct of non-profit activities, fulfilment of the financial / taxes obligations), but also operates to the highest level of ethical standards. Our Governance and Compliance Policy reflects this.